Immatics Total Stockholder Equity from 2010 to 2024

IMTXW Stock  USD 0.41  0.01  2.38%   
Immatics Biotechnologies Total Stockholder Equity yearly trend continues to be fairly stable with very little volatility. Total Stockholder Equity will likely drop to about 115.4 M in 2024. Total Stockholder Equity is the total equity held by shareholders, calculated as the difference between a company's total assets and total liabilities. It represents the net value of the company owned by shareholders. View All Fundamentals
 
Total Stockholder Equity  
First Reported
2019-03-31
Previous Quarter
387.9 M
Current Value
382.5 M
Quarterly Volatility
136.6 M
 
Covid
Check Immatics Biotechnologies financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Immatics Biotechnologies' main balance sheet or income statement drivers, such as Tax Provision of 0.0, Net Interest Income of 13.7 M or Interest Income of 14.5 M, as well as many indicators such as Price To Sales Ratio of 13.5, Dividend Yield of 0.0 or PTB Ratio of 3.58. Immatics financial statements analysis is a perfect complement when working with Immatics Biotechnologies Valuation or Volatility modules.
  
Check out the analysis of Immatics Biotechnologies Correlation against competitors.

Latest Immatics Biotechnologies' Total Stockholder Equity Growth Pattern

Below is the plot of the Total Stockholder Equity of immatics biotechnologies GmbH over the last few years. It is the total equity held by shareholders, calculated as the difference between a company's total assets and total liabilities. It represents the net value of the company owned by shareholders. Immatics Biotechnologies' Total Stockholder Equity historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Immatics Biotechnologies' overall financial position and show how it may be relating to other accounts over time.
Total Stockholder Equity10 Years Trend
Slightly volatile
   Total Stockholder Equity   
       Timeline  

Immatics Total Stockholder Equity Regression Statistics

Arithmetic Mean17,563,576
Geometric Mean57,194,609
Coefficient Of Variation556.54
Mean Deviation79,224,768
Median(41,855,000)
Standard Deviation97,748,540
Sample Variance9554.8T
Range266.9M
R-Value0.76
Mean Square Error4273.2T
R-Squared0.58
Significance0.0009
Slope16,713,484
Total Sum of Squares133766.9T

Immatics Total Stockholder Equity History

2024115.4 M
2023225.1 M
2022213.2 M
202124.1 M
2020104.3 M

About Immatics Biotechnologies Financial Statements

Immatics Biotechnologies investors use historical fundamental indicators, such as Immatics Biotechnologies' Total Stockholder Equity, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Immatics Biotechnologies. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Total Stockholder Equity225.1 M115.4 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Immatics Stock Analysis

When running Immatics Biotechnologies' price analysis, check to measure Immatics Biotechnologies' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immatics Biotechnologies is operating at the current time. Most of Immatics Biotechnologies' value examination focuses on studying past and present price action to predict the probability of Immatics Biotechnologies' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Immatics Biotechnologies' price. Additionally, you may evaluate how the addition of Immatics Biotechnologies to your portfolios can decrease your overall portfolio volatility.